The estimated Net Worth of Dennis Cho is at least $3.61 millió dollars as of 6 September 2024. Mr Cho owns over 275 units of Twist Bioscience Corp stock worth over $3,492,064 and over the last 3 years he sold TWST stock worth over $122,127.
Mr has made over 12 trades of the Twist Bioscience Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 275 units of TWST stock worth $10,769 on 6 September 2024.
The largest trade he's ever made was buying 10,000 units of Twist Bioscience Corp stock on 10 May 2023 worth over $132,000. On average, Mr trades about 334 units every 12 days since 2021. As of 6 September 2024 he still owns at least 78,721 units of Twist Bioscience Corp stock.
You can see the complete history of Mr Cho stock trades at the bottom of the page.
Dennis Cho is the Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer at Twist Bioscience Corp.
Mr Cho is 50, he's been the Sr. VP, Gen. Counsel és Chief Ethics & Compliance Officer of Twist Bioscience Corp since . There are 15 older and 7 younger executives at Twist Bioscience Corp. The oldest executive at Twist Bioscience Corp is Dr. William Charles Banyai Ph.D., 66, who is the Sr. VP of Advanced Devel., GM of Data Storage & Director.
Dennis's mailing address filed with the SEC is C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell és Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.
at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .
Twist Bioscience Corp executives and other stock owners filed with the SEC include: